518 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
REGN Regeneron Pharmaceuticals, Inc. $386.665 $41.78B N/A
Article Searches
Regeneron Reports Positive Data on Rare Blood Disorder Drug http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613 Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Piper Jaffray 31st Annual Healthcare Broker Conference Call (Transcript) https://seekingalpha.com/article/4310267-regeneron-pharmaceuticals-inc-regn-management-presents-piper-jaffray-31st-annual-healthcare?source=feed_sector_healthcare Dec 03, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Piper Jaffray 31st Annual Healthcare Conference Call December 3, 2019 08:00 a.m. ET Company Representatives Bob Landry - Chief Financial Officer Justin Ho
Alnylam Gets Second Product Approval Amid Stiff Competition http://www.zacks.com/stock/news/646584/alnylam-gets-second-product-approval-amid-stiff-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-646584 Nov 29, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
REGN or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/645048/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-645048 Nov 28, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
4 Big Biotech Stocks Worth Considering Post Q3 Earnings http://www.zacks.com/stock/news/627538/4-big-biotech-stocks-worth-considering-post-q3-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-627538 Nov 19, 2019 - We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study http://www.zacks.com/stock/news/619720/glaxos-nucala-meets-goal-in-rare-inflammatory-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-619720 Nov 14, 2019 - GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
REGN or BMRN: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/615903/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-615903 Nov 12, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
Celgene (CELG) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/614198/celgene-celg-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-614198 Nov 11, 2019 - Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Reports for Alibaba, General Electric & Anthem http://www.zacks.com/research-daily/608378/top-stock-reports-for-alibaba-general-electric-anthem?cid=CS-ZC-FT-research_daily-608378 Nov 07, 2019 - Top Stock Reports for Alibaba, General Electric & Anthem
Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/05/regeneron-pharmaceuticals-regn-q3-2019-earnings-ca.aspx?source=iedfolrf0000001 Nov 05, 2019 - REGN earnings call for the period ending September 30, 2019.

Pages: 123456...52

Page 1>